Mirum Pharmaceuticals Overview
- Year Founded
-
2018
- Status
-
Public
- Employees
-
470
- Stock Symbol
-
MIRM
- Investments
-
3
- Share Price
-
$93.30
- (As of Thursday Closing)
Mirum Pharmaceuticals General Information
Description
Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.
Contact Information
Website
www.mirumpharma.comCorporate Office
- 989 East Hillsdale Boulevard
- Suite 300
- Foster City, CA 94404
- United States
Corporate Office
- 989 East Hillsdale Boulevard
- Suite 300
- Foster City, CA 94404
- United States
Mirum Pharmaceuticals Timeline
Mirum Pharmaceuticals Stock Performance
As of 12-Nov-2026, Mirum Pharmaceuticals’s stock price is $93.30. Its current market cap is $6.09B with 65.3M shares.
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $93.30 | $94.61 | $63.23 - $130.00 | $6.09B | 65.3M | 685K | -$14.47 |
Mirum Pharmaceuticals Financials Summary
As of 30-Sep-2026, Mirum Pharmaceuticals has a trailing 12-month revenue of $671M.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 5,875,063 | 4,025,722 | 2,018,196 | 1,377,995 |
| Revenue | 670,778 | 521,312 | 336,888 | 186,374 |
| EBITDA | (877,558) | 4,479 | (62,764) | (150,225) |
| Net Income | (903,878) | (23,363) | (87,942) | (163,415) |
| Total Assets | 1,026,613 | 842,813 | 670,754 | 646,621 |
| Total Debt | 743,562 | 319,452 | 317,763 | 308,142 |
Mirum Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Mirum Pharmaceuticals Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Mirum Pharmaceuticals Comparisons
Industry
Financing
Details
Mirum Pharmaceuticals Competitors (75)
One of Mirum Pharmaceuticals’s 75 competitors is Akero Therapeutics, a Corporate Backed or Acquired company based in South San Francisco, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Akero Therapeutics | Corporate Backed or Acquired | South San Francisco, CA | ||||
| NGM Biopharmaceuticals | Private Equity-Backed | South San Francisco, CA | ||||
| Calliditas Therapeutics | Formerly VC-backed | Stockholm, Sweden | ||||
| Intercept Pharmaceuticals | Formerly VC-backed | Morristown, NJ | ||||
| Scynexis | Formerly VC-backed | Jersey City, NJ |
Mirum Pharmaceuticals Patents
Mirum Pharmaceuticals Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20260315463-A1 | Methods for treating constipation associated with cystic fibrosis | Pending | 14-Apr-2025 | ||
| US-20260285895-A1 | Processes of producing volixibat and analogs thereof | Pending | 21-Feb-2025 | ||
| WO-2026178415-A1 | Processes of producing volixibat and analogs thereof | Pending | 21-Feb-2025 | ||
| WO-2026169668-A1 | Method of reducing hepatitis b virus (hbv) infection with cavrotolimod | Pending | 04-Feb-2025 | ||
| US-20250345326-A1 | Methods for treating cholestatic pruritus | Pending | 07-May-2024 | A61K31/4995 |
Mirum Pharmaceuticals Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Mirum Pharmaceuticals Investments & Acquisitions (3)
Mirum Pharmaceuticals’s most recent deal was a Merger/Acquisition with Bluejay Therapeutics for . The deal was made on 23-Jan-2026.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Bluejay Therapeutics | 23-Jan-2026 | Merger/Acquisition | Drug Discovery | ||
| Travere Therapeutics (Bile Acid Product Portfolio) | 16-Jul-2023 | Corporate Asset Purchase | Buildings and Property | ||
| Satiogen Pharmaceuticals | 20-May-2022 | Merger/Acquisition | Pharmaceuticals |
Mirum Pharmaceuticals ESG
Risk Overview
Risk Rating
Updated November, 08, 2026
35.92 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,585
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Biotechnology
Subindustry
of 431
Rank
Percentile
Mirum Pharmaceuticals FAQs
-
When was Mirum Pharmaceuticals founded?
Mirum Pharmaceuticals was founded in 2018.
-
Where is Mirum Pharmaceuticals headquartered?
Mirum Pharmaceuticals is headquartered in Foster City, CA.
-
What is the size of Mirum Pharmaceuticals?
Mirum Pharmaceuticals has 470 total employees.
-
What industry is Mirum Pharmaceuticals in?
Mirum Pharmaceuticals’s primary industry is Pharmaceuticals.
-
Is Mirum Pharmaceuticals a private or public company?
Mirum Pharmaceuticals is a Public company.
-
What is Mirum Pharmaceuticals’s stock symbol?
The ticker symbol for Mirum Pharmaceuticals is MIRM.
-
What is the current stock price of Mirum Pharmaceuticals?
As of 12-Nov-2026 the stock price of Mirum Pharmaceuticals is $93.30.
-
What is the current market cap of Mirum Pharmaceuticals?
The current market capitalization of Mirum Pharmaceuticals is $6.09B.
-
What is Mirum Pharmaceuticals’s current revenue?
The trailing twelve month revenue for Mirum Pharmaceuticals is $671M.
-
Who are Mirum Pharmaceuticals’s competitors?
Akero Therapeutics, NGM Biopharmaceuticals, Calliditas Therapeutics, Intercept Pharmaceuticals, and Scynexis are some of the 75 competitors of Mirum Pharmaceuticals.
-
What is Mirum Pharmaceuticals’s annual earnings per share (EPS)?
Mirum Pharmaceuticals’s EPS for 12 months was -$14.47.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
